

Maria T Desancho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2030933/publications.pdf>

Version: 2024-02-01

41
papers

1,045
citations

516215

16
h-index

433756

31
g-index

42
all docs

42
docs citations

42
times ranked

1838
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 872-888. | 2.5 | 310 |
| 2 | Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2958-2967. | 1.9 | 98 |
| 3 | American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. <i>Blood Advances</i> , 2022, 6, 664-671. | 2.5 | 53 |
| 4 | Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke. <i>JAMA Neurology</i> , 2018, 75, 379. | 4.5 | 52 |
| 5 | American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021, 5, 3951-3959. | 2.5 | 49 |
| 6 | The effects of Eculizumab on the pathology of malignant atrophic papulosis. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 185. | 1.2 | 48 |
| 7 | ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 208. | 0.7 | 46 |
| 8 | D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19. <i>Thrombosis Research</i> , 2020, 196, 318-321. | 0.8 | 45 |
| 9 | Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. <i>Blood Advances</i> , 2017, 1, 2320-2324. | 2.5 | 40 |
| 10 | Prediction and Prevention of Cancer-Associated Thromboembolism. <i>Oncologist</i> , 2021, 26, e2-e7. | 1.9 | 33 |
| 11 | Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. <i>Annals of Neurology</i> , 2021, 90, 159-169. | 2.8 | 31 |
| 12 | BLEEDING AND THROMBOTIC COMPLICATIONS IN CRITICALLY ILL PATIENTS WITH CANCER. <i>Critical Care Clinics</i> , 2001, 17, 599-622. | 1.0 | 25 |
| 13 | A patient with "spontaneous" heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 73-75. | 0.5 | 25 |
| 14 | <p></p>Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 305-318. | 0.7 | 23 |
| 15 | Hematological Issues in Critically Ill Patients with Cancer. <i>Critical Care Clinics</i> , 2010, 26, 107-132. | 1.0 | 18 |
| 16 | Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2005, 18, 329-331. | 0.7 | 17 |
| 17 | Management of pregnancy in women with factor VII deficiency: A case series. <i>Haemophilia</i> , 2020, 26, 652-656. | 1.0 | 16 |
| 18 | Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 982-986. | 1.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 534-538. | 0.5 | 13 |
| 20 | Lingual thrombosis in a woman with antiphospholipid syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, e3-e4. | 0.7 | 13 |
| 21 | Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 233-239. | 1.0 | 10 |
| 22 | Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 11-15. | 0.5 | 8 |
| 23 | Peri- and Postpartum Management of Patients With Factor XI Deficiency. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988026. | 0.7 | 8 |
| 24 | Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 597-600. | 1.0 | 8 |
| 25 | Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1735-1743. | 1.9 | 8 |
| 26 | Role of Novel Anticoagulants for Patients with Mechanical Heart Valves. <i>Current Atherosclerosis Reports</i> , 2014, 16, 448. | 2.0 | 6 |
| 27 | Inherited antithrombin deficiency and anabolic steroids. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 717-719. | 0.5 | 6 |
| 28 | Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 267-271. | 1.0 | 6 |
| 29 | Adherence to guidelines for perioperative management of anticoagulation results in decreased bleeding complications. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 426-429. | 0.5 | 4 |
| 30 | Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 431-437. | 1.0 | 4 |
| 31 | Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 734-738. | 1.0 | 2 |
| 32 | Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N. <i>International Journal of Hematology</i> , 2014, 100, 602-606. | 0.7 | 1 |
| 33 | Risk of venous thrombosis varies with different types of combined oral contraceptives. <i>Evidence-Based Medicine</i> , 2014, 19, e11-e11. | 0.6 | 1 |
| 34 | Dalteparin was at least as effective as UFH for VTE prevention in critically ill patients, with similar costs. <i>Annals of Internal Medicine</i> , 2015, 162, JC13. | 2.0 | 1 |
| 35 | Delayed diagnosis of congenital sideroblastic anemia. <i>Seminars in Hematology</i> , 2018, 55, 177-178. | 1.8 | 1 |
| 36 | Management and outcomes of mild hemophiliacs and hemophilia carriers during pregnancy and peripartum period: a hemophilia treatment center experience in the United States. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 9759-9764. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Is measurement of antifactor Xa necessary in the pregnant anticoagulated patient?. American Journal of Obstetrics and Gynecology, 2003, 189, S147. | 0.7 | 0 |
| 38 | Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications. Evidence-Based Medicine, 2013, 18, 28-29. | 0.6 | 0 |
| 39 | Abstract TP72: Pilot Trial of Enoxaparin versus Aspirin in Cancer Patients with Stroke: the TEACH Study. Stroke, 2017, 48, . | 1.0 | 0 |
| 40 | Management and Outcomes of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy. Blood, 2021, 138, 1018-1018. | 0.6 | 0 |
| 41 | Impairment of Annexin A2-Mediated Cell Surface Fibrinolysis in Nonalcoholic Steatohepatitis Cirrhosis with Portal Vein Thrombosis. Blood, 2021, 138, 1030-1030. | 0.6 | 0 |